- Home
- FMN vs PRLD Comparison
FMN vs PRLD Comparison
Compare FMN & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMN
- PRLD
- Stock Information
- Founded
- FMN 2002
- PRLD 2016
- Country
- FMN United States
- PRLD United States
- Employees
- FMN N/A
- PRLD N/A
- Industry
- FMN Investment Managers
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- FMN Finance
- PRLD Health Care
- Exchange
- FMN Nasdaq
- PRLD Nasdaq
- Market Cap
- FMN 86.2M
- PRLD 69.1M
- IPO Year
- FMN N/A
- PRLD 2020
- Fundamental
- Price
- FMN $10.96
- PRLD $1.43
- Analyst Decision
- FMN
- PRLD Strong Buy
- Analyst Count
- FMN 0
- PRLD 3
- Target Price
- FMN N/A
- PRLD $4.00
- AVG Volume (30 Days)
- FMN 22.8K
- PRLD 278.8K
- Earning Date
- FMN 01-01-0001
- PRLD 11-05-2025
- Dividend Yield
- FMN 3.86%
- PRLD N/A
- EPS Growth
- FMN N/A
- PRLD N/A
- EPS
- FMN N/A
- PRLD N/A
- Revenue
- FMN N/A
- PRLD $7,000,000.00
- Revenue This Year
- FMN N/A
- PRLD N/A
- Revenue Next Year
- FMN N/A
- PRLD N/A
- P/E Ratio
- FMN N/A
- PRLD N/A
- Revenue Growth
- FMN N/A
- PRLD N/A
- 52 Week Low
- FMN $9.09
- PRLD $0.61
- 52 Week High
- FMN $11.31
- PRLD $2.08
- Technical
- Relative Strength Index (RSI)
- FMN 56.14
- PRLD 59.08
- Support Level
- FMN $10.91
- PRLD $1.33
- Resistance Level
- FMN $11.09
- PRLD $1.63
- Average True Range (ATR)
- FMN 0.06
- PRLD 0.19
- MACD
- FMN -0.01
- PRLD 0.02
- Stochastic Oscillator
- FMN 26.32
- PRLD 46.20
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.